The stock of Exact Sciences Corporation (NASDAQ:EXAS) last traded at $96.44, down -1.13% from the previous session.
Data from the available sources indicates that Exact Sciences Corporation (NASDAQ:EXAS) is covered by 22 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $130.00 and a low of $75.00, we find $105.00. Given the previous closing price of $97.54, this indicates a potential upside of 7.65 percent. EXAS stock price is now 5.61% away from the 50-day moving average and 47.56% away from the 200-day moving average. The market capitalization of the company currently stands at $17.07B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
In total, 6 analysts have assigned it a hold rating, and 14 have given it a buy rating. Brokers who have rated the stock have averaged $104.12 as their price target over the next twelve months.
With the price target enhanced from $55 to $85, Craig Hallum Upgraded its rating from Hold to Buy for Exact Sciences Corporation (NASDAQ: EXAS).
In other news, Doyle James Edward, Director sold 2,000 shares of the company’s stock on Jul 27. The stock was sold for $194,840 at an average price of $97.42. Upon completion of the transaction, the Director now directly owns 52,110 shares in the company, valued at $5.03 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 19, General Counsel Herriott James sold 1,300 shares of the business’s stock. A total of $130,000 was realized by selling the stock at an average price of $100.00. This leaves the insider owning 5,964 shares of the company worth $0.58 million. Insiders disposed of 123,868 shares of company stock worth roughly $11.95 million over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EXAS stock. A new stake in Exact Sciences Corporation shares was purchased by JENNISON ASSOCIATES LLC during the first quarter worth $42,331,000. TWINBEECH CAPITAL LP invested $26,734,000 in shares of EXAS during the first quarter. In the first quarter, ARDEVORA ASSET MANAGEMENT LLP acquired a new stake in Exact Sciences Corporation valued at approximately $18,912,000. HHLR ADVISORS, LTD. acquired a new stake in EXAS for approximately $16,404,000. CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. purchased a new stake in EXAS valued at around $15,426,000 in the second quarter. In total, there are 846 active investors with 89.30% ownership of the company’s stock.
With an opening price of $96.97 on Tuesday morning, Exact Sciences Corporation (NASDAQ: EXAS) set off the trading day. During the past 12 months, Exact Sciences Corporation has had a low of $29.27 and a high of $100.77. As of last week, the company has a debt-to-equity ratio of 0.78, a current ratio of 3.00, and a quick ratio of 2.60. The fifty day moving average price for EXAS is $91.62 and a two-hundred day moving average price translates $65.68 for the stock.
The latest earnings results from Exact Sciences Corporation (NASDAQ: EXAS) was released for Mar, 2023. According to the Diagnostics & Research Company, earnings per share came in at -$0.42, beating analysts’ expectations of -$0.75 by 0.33. This compares to -$1.04 EPS in the same period last year. The net profit margin was -23.50% and return on equity was -16.60% for EXAS. The company reported revenue of $602.45 million for the quarter, compared to $486.57 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 23.82 percent. For the current quarter, analysts expect EXAS to generate $600.14M in revenue.
Exact Sciences Corporation(EXAS) Company Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test’s performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
